NCT05256316

Risks of Bacterial and Fungal Superinfection in Patients With COVID-19

Risks of Bacterial and Fungal Superinfection in Patients With COVID-19 Stratified by New and Pre-existing Immunosuppression: a Retrospective, Observational, Multisite, Multinational Cohort Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 790 (actual)
• Sponsor: The University of Queensland · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Infection with bacteria or fungi can be deadly. Often, these types of infections can lead to an increase in the severity of illness requiring intensive care unit (ICU) admission, prolonged duration of treatment and further risks associated with additional infections and superinfections. These are also called hospital acquired secondary infections. Patients who contract COVID-19 and require an ICU admission are at increased risk of contracting these secondary infections, and receive certain medications that can lower your body's immune response. In COVID-19 patients who require these treatments, it is unclear what affect these medications can have on developing an additional infection as well as the rate of recovery/survival. This study is evaluating the effect these medications have on the development of secondary infections and rate of survival of COVID-19 patients that have been admitted to ICUs.

Conditions

• COVID-19

Interventions

Type	Name	Description
OTHER	Previously admitted COVID-19 patients in intensive care units	Exposure: this is a retrospective, observational study that does not include an intervention. Data collected for this study will be from previously hospitalized COVID-19 patients who had an intensive care unit stay during their admission

Timeline

• Start date: 2022-02-14
• Primary completion: 2022-12-04
• Completion: 2022-12-04
• First posted: 2022-02-25
• Last updated: 2023-05-22

Locations

5 sites across 5 countries: United States, Australia, India, Singapore, Thailand